US equities
|
NVDA
$237.08
▲+1.34%
SPCX
$165.04
▲+3.82%
MU
$1,064.37
▼-0.98%
TSLA
$378.96
▲+2.26%
MSFT
$526.37
▲+1.71%
INTC
$117.00
▼-1.96%
SNDK
$1,723.27
▲+0.19%
AMD
$629.41
▼-0.71%
NVDA
$237.08
▲+1.34%
SPCX
$165.04
▲+3.82%
MU
$1,064.37
▼-0.98%
TSLA
$378.96
▲+2.26%
MSFT
$526.37
▲+1.71%
INTC
$117.00
▼-1.96%
SNDK
$1,723.27
▲+0.19%
AMD
$629.41
▼-0.71%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Aligos Therapeutics
< Previous
1
2
3
4
Next >
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
October 01, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics to Present at Investor Conferences in October
September 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 24, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
HAE
NVO
PLRX
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
September 19, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
September 18, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 13, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Announces Reverse Stock Split
August 15, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Strengthens Board with Two New Independent Directors
August 08, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
August 06, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
July 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
July 10, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
June 05, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
May 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
May 21, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
May 07, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
April 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
April 25, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
April 25, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
April 09, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
April 03, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
March 27, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
March 18, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
March 05, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
February 26, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
February 20, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
February 13, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
December 07, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
November 20, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
< Previous
1
2
3
4
Next >
